Invention Application
WO2011158122A3 ANTI-HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (HENT1) ANTIBODIES AND METHODS OF USE THEREOF
审中-公开
抗人核等离子体转运蛋白1（HENT1）抗体及其使用方法
- Patent Title: ANTI-HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (HENT1) ANTIBODIES AND METHODS OF USE THEREOF
- Patent Title (中): 抗人核等离子体转运蛋白1（HENT1）抗体及其使用方法
-
Application No.: PCT/IB2011002182Application Date: 2011-06-16
-
Publication No.: WO2011158122A3Publication Date: 2012-03-01
- Inventor: SANDVOLD MARIT LILAND , CASS CAROL E , YOUNG JAMES D , MYHREN FINN
- Applicant: CLAVIS PHARMA ASA , UNIV ALBERTA , SANDVOLD MARIT LILAND , CASS CAROL E , YOUNG JAMES D , MYHREN FINN
- Assignee: CLAVIS PHARMA ASA,UNIV ALBERTA,SANDVOLD MARIT LILAND,CASS CAROL E,YOUNG JAMES D,MYHREN FINN
- Current Assignee: CLAVIS PHARMA ASA,UNIV ALBERTA,SANDVOLD MARIT LILAND,CASS CAROL E,YOUNG JAMES D,MYHREN FINN
- Priority: US35535710 2010-06-16; US201161432702 2011-01-14
- Main IPC: C07K16/18
- IPC: C07K16/18 ; A61K39/395 ; G01N33/577
Abstract:
This invention provides monoclonal antibodies that recognize hENTl. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENTl expression and/or activity.
Information query
